BCH-2763

BCH-2763 is a potent and selective thrombin inhibitor. BCH-2763 has a very high affinity for thrombin (Ki = 0.11 nM) . BCH-2763 can effectively inhibit fibrin formation, platelet aggregation, and free thrombin activity. BCH-2763 can be used for the study of thrombosis[1].

Product Specifications

CAS Number

[204641-27-0]

UNSPSC

12352209

Target

Thrombin

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

O=C([C@H]1N(CCC1)C([C@H](N)CC2=CC=CC=C2)=O)NCCCCC(NCCCCC(N[C@@H](CC(O)=O)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CCC(O)=O)C(N4[C@@H](CCC4)C(N[C@@H]([C@@H](C)CC)C(N5[C@@H](CCC5)C(N[C@H](C(O)=O)CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C64H93N11O16

Molecular Weight

1272.49

References & Citations

[1]Finkle CD, et al. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost. 1998 Feb;79 (2) :431-8.